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Abstract
High carbohydrate intake and low-grade inﬂammation cooperate with insulin resistance and hyperandrogenism to constitute an interactive
continuum acting on the pathophysiology of polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of
reproductive age characterised by oligo-anovulatory infertility and cardiometabolic disorders. The role of insulin in PCOS is pivotal both in
regulating the activity of ovarian and liver enzymes, respectively involved in androgen production and in triggering low-grade inﬂammation
usually reported to be associated with an insulin resistance, dyslipidaemia and cardiometabolic diseases. Although an acute hyperglycaemia
induced by oral glucose loading may increase inﬂammation and oxidative stress by generating reactive oxygen species through different
mechanisms, the postprandial glucose increment, commonly associated with the Western diet, represents the major contributor of chronic
sustained hyperglycaemia and pro-inﬂammatory state. Together with hyperinsulinaemia, hyperandrogenism and low-grade inﬂammation,
unhealthy diet should be viewed as a key component of the ‘deadly quartet’ of metabolic risk factors associated with PCOS pathophysiology.
The identiﬁcation of a tight diet–inﬂammation–health association makes the adoption of healthy nutritional approaches a primary preventive
and therapeutic tool in women with PCOS, weakening insulin resistance and eventually promoting improvements of reproductive life and
endocrine outcomes. The intriguing nutritional–endocrine connections operating in PCOS underline the role of expert nutritionists in the
management of this syndrome. The aim of the present review is to provide an at-a-glance overview of the possible bi-directional mechanisms
linking inﬂammation, androgen excess and carbohydrate intake in women with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endo-
crine disorder in women of reproductive age(1). PCOS is often
associated with severe insulin resistance as well as with defects
in insulin secretion, and this appears to be related to the
modulation of the activity of the key regulatory enzyme of
androgen biosynthesis, cytochrome P450c17(2). In addition,
hyperinsulinaemia inhibits the production of sex hormone-
binding globulin, which increases local availability of bioactive
testosterone(3), and works synergistically with increased levels
of luteinising hormone to enhance androgen production(4). The
PCOS phenotype results in androgen excess, oligo-anovulatory
infertility, polycystic ovaries on ultrasound examination, insulin
resistance and cardiometabolic disorders, with overweight/
obesity and visceral adiposity occurring in 30–70% of PCOS
women(5). Metabolic ﬂexibility, i.e. the ability of the organism to
adapt fuel oxidation to fuel availability by switching from lipid
oxidation to glucose oxidation and vice versa, is impaired in
women with PCOS as the consequence of insulin resistance and
compensatory hyperinsulinaemia(6). In PCOS women, serum
androstenedione levels are well correlated with insulin sensi-
tivity, and the severity of glucose intolerance increases along
with the severity of the hyperandrogenic phenotype(7). In line
with these observations, analysis of First National Health and
Nutrition Examination Survey (NHANES I) data suggested
that obesity and extreme obesity affecting women by the age of
20–24 years up to 32–41 years could suggest an underlying
PCOS state which deserves appropriate workup(8).
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PCOS shares a state of low-grade inﬂammation with other
atherosclerosis-related non-transmissible chronic diseases, such
as obesity, type 2 diabetes mellitus and CVD(9,10). Among
several environmental determinants, a number of nutrients
are known to cause or modulate the inﬂammatory status and
contribute to the onset and maintenance of cardiometabolic
diseases(11–13). Nevertheless, the spectrum of nutrients respon-
sible for the onset of a pro-inﬂammatory state is also strictly
associated with obesity, which per se is associated with chronic
low-grade inﬂammation(11,14). Besides the evidence linking
inﬂammation and PCOS, uncertainty remains on the role of diet
in controlling inter-individual variability in insulin resistance,
hyperandrogenism and chronic low-grade inﬂammation
in PCOS.
In light of the increased risk of reproductive and health-related
issues in PCOS women across their life course, the aim of the
present review is to provide an at-a-glance overview of the
possible bi-directional mechanisms linking inﬂammation, andro-
gen excess and carbohydrate intake in women with PCOS.
Nutrition and inﬂammation
General concepts
The innate (non-speciﬁc) immune system, the ﬁrst-line defence
mechanism against invading pathogens(11), is able of promoting
a chronic low-grade systemic inﬂammation state(15,16), in the
absence of any systemic or local infection(15), which is usually
deﬁned by the occurrence of 2- to 3-fold increase in plasma
concentrations of cytokines and acute-phase proteins, with acti-
vation of a complex network of inﬂammatory signalling path-
ways. Among the environmental modiﬁable risk factors for
chronic inﬂammation, unhealthy nutritional patterns are emerging
for their association with the aberrant activation of the innate
immune system triggering chronic low-grade systemic inﬂam-
mation(17). Strategic interest in diet-induced inﬂammation stem-
med from both experimental and clinical evidence depicting a
role for diet in driving atherogenesis through stimulation of the
processes relating to initiation, progression and rupture of the
atherosclerotic plaque(18). Consequently, chronic low-grade sys-
temic inﬂammation has been proposed as a potential link
between insulin resistance, the metabolic syndrome, obesity,
type 2 diabetes mellitus and CVD(19). As summarised in a recent
review(11), the International Life Sciences Institute’s European
Branch (ILSI Europe) has extensively investigated the interaction
between nutrition, food and inﬂammation. However, the varia-
bility in results across different dietary studies did not allow
to draw ﬁnal conclusions on the understanding of diet/nutrient-
driven inﬂammation(11). Despite the overall consensus on the
ability of several foods and nutrients to modulate inﬂammation
both acutely and chronically, a debate currently exists on which
circulating marker best reﬂects the low-grade inﬂammation, and
which experimental condition most appropriately detects the
diet/nutrient-driven inﬂammation, i.e. the fasted v. the post-
prandial state(20). This controversy is further reinforced when
considering that circulating inﬂammatory markers may not
necessarily reﬂect the inﬂammation in tissue compartments or
what happens locally in response to inﬂammatory challenges(11).
An increase in inﬂammation occurs acutely following meal
ingestion and lasts for about 4–8 h, although it has been
reported to occur several times a day following eating(21).
Unhealthy dietary patterns and single food components have
been shown to induce inﬂammation through both direct and
indirect effects, these latter being mediated by accumulation in
white adipose tissue (WAT) of dysfunctional adipocytes and
immune cell inﬁltration leading to the release of inﬂammatory
cytokines(14,17,22). Cell populations englobed in WAT consist of
pre-adipocytes and mature adipocytes, as well as immune and
stromal cells. Pre-adipocytes have functional characteristics and
transcriptional patterns of multipotent cells that are similar to
immune cells, and can transdifferentiate into macrophages both
in vitro and in vivo(23,24). Mature adipocytes share the ability
with immune cells to secrete cytokines and activate the com-
plement cascade much like mononuclear immune cells (MNC),
then promoting a shift toward dominance of pro-inﬂammatory
adipokines as opposed to anti-inﬂammatory adipokines(25).
Upon fat accumulation, adipose tissue (AT)-derived factors can
activate CD8+ T cells and promote macrophage inﬁltration,
which perpetuates the inﬂammatory response within the AT(26).
WAT contains resident M2-like macrophages, which have a role
in AT homeostasis, and recruits M1-like macrophages, which
are clustered in crown-like structures and contribute to
inﬂammation and insulin resistance(27–30). Macrophage inﬁltra-
tion predominates in omental v. subcutaneous fat and becomes
exaggerated with central obesity, which is at higher risk of
insulin resistance(31). Post-absorptively, abdominal adipocytes
and monocytes/macrophages show the ability to respond to
acute postprandial elevation of several metabolic components
of the meal, for example, TAG, SCFA, oxysterols and glucose,
through a transient inﬂammatory response that is crucial for the
development of insulin resistance, the metabolic syndrome and
atherosclerosis(21). The resulting excess of body fat and ectopic
fat storage could give rise to a condition of lipotoxicity and a
pro-inﬂammatory/pro-oxidative state, linking nutrition to
increased cardiovascular risk(11). Because a detailed description
of the inﬂammatory effects of each single nutrient is beyond the
scope of the present review, we will focus in the next sections
on the link between carbohydrates and inﬂammation, with
particular regard to the interactions between nutrition, insulin
resistance with compensatory hyperinsulinaemia, hyperan-
drogenism and low-grade inﬂammation in women with PCOS.
Carbohydrates and inﬂammation
Postprandial hyperglycaemia, an independent predictor of
diabetes and CVD, may induce oxidative stress, i.e. the imbal-
ance between free radical production and in vivo antioxidant
defences(32), which displays a positive correlation with the
degree of hyperglycaemia(33). Both oxidative stress and
inﬂammation have overlapping detrimental effects that make
their individual effects virtually indistinguishable(34). Acute
hyperglycaemia induced by oral glucose loading has been
demonstrated to increase inﬂammation and oxidative stress by
generating reactive oxygen species (ROS) through different
mechanisms, including non-enzymic glycation and imbalance
in the NADH:NAD ratio induced by glucose(35), in several cell
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types ranging from immune cells, including MNC, activated
macrophages and T and B cells, and non-immune cells like
adipocytes. In immune cells, ROS production is essential for
eliminating invading pathogens, but it may also result in pro-
moting sterile inﬂammation associated with the activation of
phagocytes(36). In particular, when an excess of glucose (or
NEFA) reaches MNC and activated macrophages(37), a large
number of reducing metabolites, including pyruvic acid and
acetyl coenzyme A, are oxidised in mitochondria, leading to an
enhanced activity of the electron transport chain and single
electron transfer, which ﬁnally results in an increased ROS
production(38). ROS generation is an early key event in the
onset and progression of a number of different diseases(39), and
may cause oxidative modiﬁcation of LDL-cholesterol, which is
considered to be a main determinant of the development of
atherosclerosis(40). ROS can act as a potential activator of a class
of proteins involved in innate immunity, known as Toll-like
receptors, thereby mediating the activation and expression in
MNC and activating macrophages of NF-κB, a family of tran-
scription factors prone to control apoptosis and pro-
inﬂammatory cytokine expression via dissociation from the
inhibitory protein, inhibitory κB(36). In immune and non-
immune cells, activated NF-κB translocates to the nucleus and
promotes the transcription of cytokine genes capable of
enhancing the release of pro-inﬂammatory cytokines, such as
TNF-α, a known mediator of insulin resistance, IL-6, IL-1β,
monocyte chemotactic protein-1 and plasminogen activator
inhibitor-1(41). Other pro-inﬂammatory transcription factors are
also activated, including activator protein-1, forkhead box P3,
interferon regulatory factor and signal transducer and activator
of transcription families(42). Pro-inﬂammatory cytokines stimu-
late the liver to produce a variety of proteins known as acute-
phase reactants, including C-reactive protein (CRP). CRP is
involved in endothelial dysfunction and atherosclerotic process,
and its level serves as an index of vascular inﬂammation and
major predictor of CVD risk(43). IL-6 plays a key role in the liver
synthesis of CRP, and increased levels of IL-6 are correlated
with a greater occurrence of cardiac events(44). In addition, IL-6
regulates the secretion of TNF-α, which induces the expression
of adhesion molecules, such as vascular cell adhesion protein-1
and intercellular adhesion molecule-1(45). These latter have
been involved in the development of atherosclerosis and pro-
duction of other inﬂammatory cytokines(44).
Dietary carbohydrates and inﬂammation
The effect of postprandial glucose excursions mostly depends
on the time of exposure to the postprandial glucose peak, a
major contributor of chronic sustained hyperglycaemia, as well
as on the magnitude of postprandial spikes, a reﬂection of
glucose variability, with both contributing to protein glycation
and activation of oxidative stress and inﬂammation. These two
main mechanisms can lead to diabetic and cardiovascular
complications(11). Esposito et al.(46) reported that hypergly-
caemic spikes are able to affect cytokine concentrations more
than continuous hyperglycaemia, at least in the short term,
suggesting that an oxidative mechanism could mediate the
effect of hyperglycaemia. In a number of studies, the
inﬂammatory effects of carbohydrates were analysed in asso-
ciation with the glycaemic index (GI) of foods, an index
quantifying the postprandial blood glucose responses to the
carbohydrate in different foods(47,48), and the glycaemic load
(GL), the product of the GI of a speciﬁc food and its carbohy-
drate content(49), which provide an indication of glucose
available for energy or storage following a carbohydrate-
containing meal. There is evidence supporting the beneﬁts of
low-GI dietary patterns on insulin resistance(50,51), while foods
with a high GI exert opposite effects(52). Nevertheless, the
relationship between dietary GI or GL and low-grade inﬂam-
mation remains debatable, and the usefulness of GI and GL has
been questioned due to the failure to consider the high intra-
and inter-subject variation in insulin and glucose response to
the ingestion of speciﬁc foods, as well as when foods are
combined in a mixed meal(53).
Among the pro-inﬂammatory dietary patterns, particular
concern has been raised by high-energy diets with high content
in complex carbohydrates, as well as foods with a high GI scale,
low in ﬁbres, rich in reﬁned carbohydrate, or high in fat, all of
which are collectively included in the so-called Western
diet(46,54–56). The Western diet is responsible for supra-
physiological postprandial spikes in glucose and lipids, result-
ing in a pro-inﬂammatory state(17,57,58). Hu et al.(59) observed a
positive association between dietary GI and oxidative stress
markers as measured in healthy adults by two lipid peroxida-
tion markers, such as malondialdehyde and F2-isoprostanes,
thus concluding that a low-GI diet, not a low-carbohydrate diet,
could be beneﬁcial in reducing oxidative stress. The pro-
inﬂammatory effects of high-GI diets have also been conﬁrmed
in large epidemiological studies. In particular, in the Harvard
Women’s Health Study, serum CRP levels increased progres-
sively across quintiles of dietary GI(60). In addition, high-GI
carbohydrates have been reported to increase NF-κB activation
and NF-κB binding in MNC of young, lean healthy subjects(61),
such that levels of NF-κB were expressed at three times higher
levels among lean subjects consuming high-GI meals when
compared with controls(62). On the other hand, studies have
suggested that healthy eating patterns are characterised by
reduced postprandial glycaemia and lipaemia, and are asso-
ciated with reduced concentrations of low-grade inﬂammation
markers. For example, dietary patterns with low GI(62,63) or high
ﬁbre consumption are associated with lower serum concentra-
tions of CRP(64), which are conceivably related to a beneﬁcial
effect on glycaemia(65). Likewise, diets low in GL and high in
whole grains were found to exert a protective effect against
inﬂammation in diabetic patients(66), and an inverse relationship
was reported in epidemiological studies between CRP levels
and dietary intake of ﬁbre, such as in individuals receiving the
Dietary Approaches to Stop Hypertension (DASH) diet, which is
naturally high in ﬁbre (g ﬁbre/d) or consists of a ﬁbre-
supplemented standard diet (30 g psyllium ﬁbre/d)(11). At
odds with these observations, the Women’s Health Initiative
Observational Study reported that a relatively high consumption
of both soluble and insoluble ﬁbre (24 g/d) was inversely
associated with IL-6 and TNF-α but not with CRP levels(67).
Probably, the inﬂammatory response may vary depending on
the type of carbohydrate. As such, Kallio et al.(68) reported that
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a 12-week oat–wheat–potato diet resulted in a higher post-
prandial insulin response leading to late hypoglycaemia com-
pared with a rye–pasta diet. Moreover, a carbohydrate-rich diet
up-regulated genes relating to metabolic stress in abdominal
subcutaneous AT of men and women with the metabolic syn-
drome, even in the absence of changes in body weight and
insulin sensitivity(68). Finally, it is important to consider that
fructose, a common plant-derived sweetener that is habitually
consumed in diets rich in carbohydrates and lipids, promotes a
greater pro-inﬂammatory state than glucose, and its effects are
ampliﬁed when it is associated with glucose and lipids. In fact,
chronic consumption of fructose generates 100 times more ROS
than glucose through different mechanisms, such as hepatic
phosphate deﬁciency, and its hepatic metabolism generates
potent glycation agents, such as methylglyoxal, leading to cel-
lular stress and altered insulin signalling(69,70). Hepatic phos-
phate deﬁciency leads to the accumulation of AMP resulting in
the increased production of uric acid, which in turn stimulates
the production of ROS via activation of transforming growth
factor-β and NADPH oxidase 4(69). In addition, fructose has
been shown to promote the synthesis of SFA, such as palmi-
tate(71), which are channelled to distinct cellular metabolic fates
with direct and indirect involvement in the development of
insulin resistance in adipocytes and skeletal muscle cells(72).
Nutrition and inﬂammation in polycystic ovary syndrome
A pro-inﬂammatory state has emerged as a key contributor to
insulin resistance and CVD risk factors in PCOS women(10).
Besides the established role of abdominal adiposity, there is a
suggestion that metabolic and ovarian dysfunction associated
with PCOS could be enhanced by nutrient-induced oxidative
stress and inﬂammation(73). As well as in obesity and type 2
diabetes mellitus, also in PCOS inﬂammation contributes to
generate insulin resistance and compensatory hyper-
insulinaemia(74), although peculiar mediators such as hyperan-
drogenism play a pivotal role in metabolic outcomes related to
the syndrome. Both hyperinsulinaemia and hyperandrogenism
act as promoters of inﬂammation in PCOS, and the triad of
insulin resistance, hyperandrogenism and low-grade inﬂam-
mation works bi-directionally in a self-perpetuating vicious
cycle that underlies the pathophysiology of PCOS(75). The direct
exposure of ovarian theca cells to pro-inﬂammatory stimuli
in vitro increases androgen production, while in vivo circulat-
ing and molecular markers of oxidative stress and inﬂammation
are highly correlated with circulating androgens(76). Pioneering
studies by Dunaif & Graf(77) demonstrated that circulating
androgens are inﬂuenced by insulin levels independent of
variations of gonadotropin release only in PCOS women, while
such a correlation is not present in control women. It is also
worth noting that up to 50% of hyperandrogenic women with
PCOS are of normal weight and insulin sensitive(78), and
increased circulating androgens might exert anti-inﬂammatory
effects through their lipolytic action(79). It is also worth noting
that the activity of the sympathetic nervous system, which
controls resting energy expenditure at the systemic and local
levels(80), is enhanced in PCOS as much as in obesity, insulin
resistance and hypertension(81,82). Rodent models of PCOS
demonstrated an increased ovarian sympathetic outﬂow and
elevated intra-ovarian synthesis of nerve growth factor, which
may be involved in triggering ovarian disease(82). Patients with
PCOS have evidence of increased muscle sympathetic nerve
activity, altered heart rate variability and attenuated heart rate
recovery post-exercise, compared with age- and BMI-matched
controls, suggesting a generalised increase in sympathetic ner-
vous system activity(83). Whether targeting sympathetic over-
activity in this condition has favourable effects warrants further
investigation.
A potential key role in the pathophysiology of PCOS is played
by nutrients like glucose and saturated fat, which can promote
inﬂammation in women with PCOS and stimulate ovarian
androgen production independent of excess adiposity and
insulin resistance(73,74). Most studies examining markers of the
pro-inﬂammatory state in PCOS have focused on the mea-
surement of circulating CRP and adiponectin levels(84,85). The
antidiabetic, anti-inﬂammatory, anti-atherogenic and cardio-
protective effects of adiponectin are widely recognised, where
the high-molecular-weight isoforms represent the major rele-
vant forms in its insulin-sensitivity activities(86). However, pre-
vious reports on serum adiponectin levels in women with PCOS
have provided conﬂicting results(87). Like in CVD and obe-
sity(88), also in PCOS patients CRP levels are a reliable circu-
lating marker of chronic low-grade inﬂammation(11), although
adiposity is a potential confounding determinant of CRP ele-
vations in PCOS, and CRP is expressed at levels that are below
the range predictive of metabolic or CVD risk(76). Of note, MNC
make use of ingested glucose and lipids for mitochondrial
respiration during energy metabolism and generate NADPH
oxidase, the ROS-producing enzyme, which in turn promotes
the transcription of TNF-α and IL-6 genes. MNC have been
extensively investigated in relation to the link connecting diet to
inﬂammation in PCOS, especially when considering that dietary
components, such as glucose and lipids, can trigger an
inﬂammatory response in MNC(76). Glucose ingestion is a pro-
moting mechanism of inﬂammation in PCOS, as it has been
shown to activate NF-κB in MNC and in MNC-derived macro-
phages migrating into the stromal–vascular compartment of
expanded AT of obese individuals in response to cell
hypoxia(28,74). González et al.(74) demonstrated that glucose
ingestion in women with PCOS stimulated ROS-related oxida-
tive stress and increased NF-κB activation independent of
obesity. These authors further observed that MNC-derived
cytokine release was inversely related to insulin sensitivity and
directly related to androgens, thus leading to the hypothesis that
the glucose-stimulated inﬂammatory response from MNC
played an independent role in promoting insulin resistance,
hyperandrogenism, as well as inﬂammation in PCOS(74). Gon-
zález(76) summarised the evidence that TNF-α and IL-6 release
from circulating MNC is increased in PCOS both upon glucose
ingestion in vivo and after glucose exposure in vitro, and is
associated with insulin resistance, thus suggesting that diet-
induced inﬂammation in PCOS is linked to insulin resistance
and atherogenesis. In this scenario, nutrition could represent
a complementary component of a new ‘deadly quartet’ of
metabolic risk factors for PCOS in association with hyper-
insulinaemia, hyperandrogenism and low-grade inﬂammation,
N
ut
ri
tio
n 
R
es
ea
rc
h 
R
ev
ie
w
s
294 L. Barrea et al.
https://doi.org/10.1017/S0954422418000136
Downloaded from https://www.cambridge.org/core. Biblioteca Interdip Ing, on 06 Mar 2019 at 08:39:43, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
with hyperandrogenism possibly acting as a precursor of
diet-induced inﬂammation(76). The results of clinical trials set
up to investigate in vivo the effects of anti-inﬂammatory therapy
on circulating ovarian androgens in women with PCOS
following lipid ingestion and glucose infusion will lead to an
understanding of these intriguing nutritional–endocrine
connections(89).
Indeed, diet is a key determinant of excessive body weight in
PCOS and its relationship with PCOS is possibly inﬂuenced by
geographical determinants(90). A survey on overweight and
obese US women with PCOS-related infertility showed poor
dietary intake, particularly in terms of whole grains, ﬁbre, and
Fe, and eating behaviours inconsistent with achieving a healthy
body weight, as well as low scores for PCOS-related quality of
life(91). Dissimilarly, a study on overweight and obese Italian
PCOS women found no difference in terms of energy, macro-
nutrient and advanced glycosylated end-product intake as
compared with controls, yet PCOS women were characterised
by a higher consumption of cheese and high-GI starchy sweets
and a preference for raw oil rather than other cooked fats(5).
Women with PCOS showed impaired satiation and alterations in
satiety–appetite hormones, for example, lower baseline levels
and responsiveness of ghrelin to meals with varying carbohy-
drate content as well as higher leptin concentrations than
BMI-matched controls(92–94). On the other hand, it is widely
recognised that body weight reduction yields marked beneﬁcial
effects on insulin resistance, hyperandrogenic phenotype and
gynaecological problems of PCOS women(95) and PCOS may
even resolve after weight loss induced by bariatric surgery(96).
A healthy dietary habit with an adequate ratio of complex to
simple carbohydrates appears to be appropriate in light of the
link between nutrition, hyperinsulinaemia, hyperandrogenism
and chronic low-grade inﬂammation, and a low-fat/high-com-
plex carbohydrate diet can promote weight loss and ameliorate
metabolic, hormonal and reproductive homeostasis of PCOS(97).
There is, however, evidence that the chemical structure of food
and botanical structure rather than the amount of ﬁbre or the
type of cereal in the food determine postprandial insulin
responses to grain products and insulin resistance(98), and these
effects may be mediated through glucose insulinotropic peptide
and glucagon-like peptide-1(99,100). It is also worth noting that
metabolic inﬂexibility in insulin-resistant individuals fails to
adequately oxidise fatty acids, and it diminishes the ability to
switch from glucose to lipid oxidation during overnight fasting,
thus leading to lipid accumulation in skeletal muscle and further
impairment of insulin signalling(101). Weight loss can improve
insulin-mediated suppression of fatty acid oxidation in insulin-
resistant individuals(102,103) and prevents the effects of hyper-
insulinaemia on weight gain(104).
Dietary intervention in polycystic ovary syndrome
Dietary modiﬁcations that lead to a reduction in postprandial
glucose and hyperinsulinaemia could have important implica-
tions in improving fatty acid oxidation, promoting weight loss,
and preventing further weight gain in women with PCOS(105). In
a prospective study in infertile women seeking counselling,
total carbohydrate intake and dietary GL were found to be
positively related to ovulatory infertility in analyses adjusted for
age, BMI, smoking, parity, physical activity, recency of contra-
ception, total energy intake, protein intake and other dietary
variables(106). In PCOS women, uncertainty remains on whether
manipulation of dietary components could aid the clinical
management of the syndrome. Recent interest has stimulated
research on moderate increases in dietary protein as a strategy
to tackle global problems of PCOS, for example, glucose intake,
androgen alterations, weight accrual and cardiometabolic
risk(107,108). In a cross-over study, Douglas et al.(109) reported
that a low-carbohydrate diet (43% of total energy) for 16 d can
promote signiﬁcant reductions in fasting and post-challenge
insulin concentrations, which may over time improve the
reproductive and endocrine outcomes of PCOS women. These
results were conﬁrmed by Marsh et al.(110) in ninety-six PCOS
women, in which changes in insulin sensitivity and clinical
outcomes were assessed during a dieting programme achieving
similar weight loss (4–5% of initial body weight) after con-
sumption of a low-GI diet compared with a conventional
healthy diet for 12 months. Both diets were designed as
reduced-energy, low-fat, low-saturated fat, moderate-to-high-
ﬁbre diets with similar macronutrient distribution but differing
carbohydrate content (GI, 40 v. 59%; GL, 74 v. 109 g). Of
interest, this study evidenced that with modest weight loss both
the treatments led to similar improvements in blood lipids,
androgens and markers of inﬂammation, but only women on a
low-GI diet showed improvements in menstrual disorders,
whole-body insulin sensitivity and levels of ﬁbrinogen, an
acute-phase protein of inﬂammation(110). In evaluating the
inﬂammatory pattern, Mehrabani et al.(111) investigated the
effects of a high-protein, low-GL hypoenergetic diet (40% car-
bohydrates with <20 GL, 30% protein, 30% fat) as compared
with a conventional hypoenergetic diet (55% carbohydrate,
15% protein, 30% fat) on reproductive hormones, inﬂammatory
markers, lipids, glucose and insulin levels in sixty obese women
with PCOS. Results demonstrated that both diets signiﬁcantly
led to reduced body weight and androgen levels, but only the
combination of high-protein and low-GL foods led to a sig-
niﬁcant increase in insulin sensitivity and a decrease in high-
sensitivity CRP levels(111). Subsequently, Gower & Goss(112)
evaluated if dietary restriction of carbohydrates would beneﬁt
body composition and metabolic health in thirty women with
PCOS randomised to receive a low-fat diet (55, 18 and 27% of
energy from carbohydrate, protein and fat, respectively) or a
low-carbohydrate diet (41, 19 and 40%, respectively) for
8 weeks. The low-carbohydrate diet resulted in signiﬁcant
decreases in fasting insulin and glucose, and a signiﬁcant
increase in insulin sensitivity, while no changes were observed
consuming the low-fat diet. While markers of inﬂammation did
not change in response to either of the two diets, changes in
intra-abdominal AT were associated with changes in TNF-α
levels independent of changes in total body fat mass(112).
Different studies showed that carbohydrates from dairy pro-
ducts and starch-based foods caused greater postprandial
insulin secretion than carbohydrates from non-starchy vege-
tables and fruits. In a prospective 8-week dietary intervention
using a low-starch/low-dairy product diet, Pohlmeier et al.(113)
reported that this approach proved useful in increasing fat
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oxidation in overweight and obese women with PCOS. More
recently, Eslamian et al.(114) investigated in a case–control study
the association between dietary carbohydrate components and
PCOS using a validated semi-quantitative FFQ. The results of
this study showed higher dietary GI and GL values in women
with PCOS than controls, while ﬁbre intake was inversely
associated with PCOS.
In a study investigating the effects of fructose in PCOS, Johnson
et al.(115) examined whether an 8-week low-fructose, low-energy
diet could be superior to a traditional low-energy diet based on
fructose-rich liquid meal replacements, with respect to improve-
ment of cardiometabolic risk factors and reproductive hormones.
The authors failed to obtain signiﬁcant differences between the
two diet regimens in terms of body weight reduction, modiﬁca-
tion in cardiometabolic risk factors, including CRP levels and
androgens. Little but positive experience has been reported on a
low-energy ketogenic diet (consisting of fewer than 20 g carbo-
hydrate per d) in PCOS women in terms of body weight, free
testosterone, luteinising hormone:follicle-stimulating hormone
ratio and fasting insulin(116). It is also expected that manipulation
of dietary protein content could favour psychological outcomes in
PCOS women, namely depression and self-esteem, and predis-
pose to improvement in satiety, dietary compliance and steroid
production(117). Regarding safety issues, it is until now unclear
how low the carbohydrates content of a diet should be or for how
long a low-carbohydrate diet can be administered so as to achieve
optimal results without potential adverse events(118). Challenging
these previous views, however, there is suggestion that energy
restriction seems more important than macronutrient composi-
tion, and there is still little evidence to support a universal role
for high-protein diets on PCOS outcomes relating to fertility,
endocrine/metabolic parameters and weight loss(119,120).
Since oxidative stress and inﬂammation occur in PCOS even in
the absence of excess adiposity, a promising approach could be
represented by dietary strategies that are capable of preventing
inﬂammation, and hence insulin resistance. Anti-inﬂammation
nutrition works upstream of primary molecular targets of
inﬂammation to reduce the dietary factors that activate NF-κB to
generate silent inﬂammation. Anti-inﬂammatory approaches
encompassing low-GL foods, low n-6 fatty acids content and high
n-3 fatty acids, combined according to the 1-2-3 nutritional rule-
of-thumb proposed by the International Sports Sciences Asso-
ciation for macronutrients ratio (approximately one part fat, two
parts protein and three parts carbohydrates), have been shown to
improve insulin resistance and metabolic outcomes in the general
population(121). Also, dietary intake of nuts, a source of MUFA and
n-3 PUFA, is increasingly seen as a strategy to exert beneﬁcial
effects on lipids, androgens and possibly inﬂammatory markers in
PCOS women(122). Growing interest is focusing on the effects of
the Mediterranean diet on PCOS outcomes(123,124). As such,
energy restriction and a healthy lifestyle along with an anti-
inﬂammatory nutrition approach are all reckoned as beneﬁcial for
PCOS outcomes, particularly when low-GI foods are associated
with the Mediterranean diet, decreased red/processed meat, low
sugar and saturated fats, phytochemicals and antioxidants, as well
as small frequent meals(123). A 12-week study in seventy-ﬁve
overweight women using a Mediterranean-inspired low-GL
hypoenergetic diet (25% protein, 25% fat and 50% carbohydrate)
showed favourable effects on body composition, menstrual
cyclicity, blood pressure, glucose homeostasis, dyslipidaemia and
surrogate measures of CVD risk(125). Likewise, the DASH diet has
gained increasing interest in the dietary management of PCOS
patients due to its dietary content of antioxidant foods, such as
fruits, vegetables, whole grains, low-fat dairy products and ions
along with low saturated fats, cholesterol, reﬁned grains and
sweets(126). Compared with a control group, consumption of a
hypoenergetic DASH eating pattern for 8–12 weeks in overweight
and obese women with PCOS resulted in the improvement of
insulin resistance, TAG, VLDL-cholesterol and serum high-
sensitivity CRP levels, and a signiﬁcant increase in antioxidant
levels along with improvements in abdominal fat accumula-
tion(127–129). Together, this evidence suggests that women with
PCOS should be advised to consume a diet that includes an
increase in ﬁbre and a decrease in reﬁned carbohydrates, as well
as a decrease in trans- and saturated fats and an increase in n-3
(and n-9) fatty acids. Foods that contain anti-inﬂammatory com-
pounds (ﬁbre, n-3 fatty acids, vitamin E and resveratrol) could
also help improving the metabolic and hyperandrogenic proﬁle of
PCOS patients(130). In addition, vitamins such as vitamin C and β-
carotene, inositol that belongs to the group of B vitamins, vitamin-
like coenzyme Q10, minerals, such as Zn, Cu, Mg and Se, and
other compounds, including resveratrol and N-acetyl cysteine,
have been suggested as auxiliary antioxidants in PCOS. All these
antioxidants could either stop directly the oxidation chain reaction
or enhance the activity of main antioxidants; nevertheless, sys-
tematic reviews and meta-analyses of randomised controlled trials
have been provided only on a restricted number of these
compounds(131–134).
Conclusions
Epidemiological studies and large clinical trials have identiﬁed
a number of potential diet-derived anti-inﬂammatory and
pro-inﬂammatory components involved in the pathogenesis of
PCOS, particularly those linking carbohydrate intake to low-grade
chronic inﬂammation. Mutually with hyperinsulinaemia, hyper-
androgenism and low-grade inﬂammation, an unhealthy diet
should be thus viewed as a key component of the ‘deadly quartet’
of metabolic risk factors associated with PCOS pathophysiology,
as depicted in Fig. 1. Although it is evident that the inﬂammatory
response driven by carbohydrates is highly variable and that a full
understanding of the source of heterogeneity is lacking, the
results of large clinical trials set up to investigate in vivo the effects
of anti-inﬂammatory therapy on circulating ovarian androgens in
women with PCOS will lend support to the hypothesis of these
intriguing nutritional–endocrine connections. The recognition of a
robust diet–inﬂammation–health association makes the adoption
of healthy nutritional approaches a key future preventive and
therapeutic target in PCOS. A rational approach to the dietary
management of women with PCOS under the guidance of
registered dietitians will help the endocrinologists engage with
these patients and increase the knowledge of how diet and life-
style factors inﬂuence the disorder and how they may be changed
to improve prognosis without exclusive reliance on only phar-
macological treatments. Considering the substantial role of
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chronic low-grade inﬂammation in the pathogenesis of numerous
chronic diseases, and acknowledging the health problems relating
to PCOS in women across their entire life course, including
infertility and long-term cardiometabolic consequences, there is a
need to implement the strategic nutritional approach by expert
dietitians, so as to design appropriate anti-inﬂammatory dietary
interventions for the prevention and treatment of diet-induced
inﬂammation in PCOS.
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